Fig. 1: Antibody responses after bivalent COVID-19 booster vaccination. | npj Vaccines

Fig. 1: Antibody responses after bivalent COVID-19 booster vaccination.

From: Bivalent mRNA booster vaccination recalls cellular and antibody immunity against antigenically divergent SARS-CoV-2 spike antigens

Fig. 1

A Study design: healthy adults (n = 33) were administered a bivalent mRNA vaccine. Blood samples were collected pre-vaccination day (D)-0, and at days 7, 14, 28 and 84 post-vaccination. B IgG antibody endpoint titres against SARS-CoV-2 Nucleocapsid (N) protein. Individuals with a >4-fold change in titre are indicated in blue. C IgG antibody endpoint titres against Ancestral and D Omicron BA.1 spikes. E Neutralisation titres calculated by 50% virus inhibitory concentration (IC50) against Ancestral and F Omicron BA.1 live viruses. Geometric mean titres (GMT) and geometric mean ratios (GMR) are shown above each graph. For C–F, n = 32 at D0, D7, and D14; n = 31 at D28 and n = 17 at day 84. Asterisk indicates p value of Kruskal–Wallis test with Dunn’s post-test comparing D0 with D7, 14, 28 or 84. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Back to article page